NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, News, & Analysis

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $11.11 million during the quarter, compared to analyst estimates of $15.65 million. View Synergy Pharmaceuticals' Earnings History.

Synergy Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Synergy Pharmaceuticals.

5 Wall Street analysts have issued twelve-month price objectives for Synergy Pharmaceuticals' shares. Their forecasts range from $7.00 to $7.00. On average, they expect Synergy Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 2,233.3% from the stock's current price. View Analyst Price Targets for Synergy Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Synergy Pharmaceuticals.

Media coverage about SGYP stock has trended neutral this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.

Synergy Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 18,430,902 shares, an increase of 8.9% from the January 15th total of 16,919,869 shares. Based on an average daily trading volume, of 13,023,997 shares, the short-interest ratio is currently 1.4 days. Currently, 7.5% of the company's stock are short sold. View Synergy Pharmaceuticals' Current Options Chain.

Some companies that are related to Synergy Pharmaceuticals include XBiotech (XBIT), American Brivision (Holding) (ABVC), Aduro BioTech (ADRO), Constellation Pharmaceuticals (CNST), Magenta Therapeutics (MGTA), Aclaris Therapeutics (ACRS), Neptune Wellness Solutions (NEPT), OptiNose (OPTN), Minerva Neurosciences (NERV), Adamas Pharmaceuticals (ADMS), Evelo Biosciences (EVLO), Geron (GERN), BIOFRONTERA AG/ADR (BFRA), Catalyst Pharmaceuticals (CPRX) and Axsome Therapeutics (AXSM).

Synergy Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.87%), Northern Trust Corp (1.00%), Opti Capital Management LP (0.35%), Geode Capital Management LLC (0.30%), Bank of New York Mellon Corp (0.27%) and Rhumbline Advisers (0.13%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

SGYP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Northern Trust Corp and Bank of New York Mellon Corp. View Insider Buying and Selling for Synergy Pharmaceuticals.

SGYP stock was bought by a variety of institutional investors in the last quarter, including Opti Capital Management LP, Paloma Partners Management Co and Rhumbline Advisers. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGYP stock can currently be purchased for approximately $0.30.

Synergy Pharmaceuticals has a market capitalization of $74.41 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

The official website for Synergy Pharmaceuticals is http://www.synergypharma.com.

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]